These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11388581)

  • 1. Statin induced myopathy does not show up in MIBI scintigraphy.
    Lupattelli G; Palumbo B; Sinzinger H
    Nucl Med Commun; 2001 May; 22(5):575-8. PubMed ID: 11388581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
    Hoffman KB; Kraus C; Dimbil M; Golomb BA
    PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Statin therapy and muscle disorders].
    Abel T; Fehér J
    Orv Hetil; 2009 Feb; 150(6):261-3. PubMed ID: 19179258
    [No Abstract]   [Full Text] [Related]  

  • 4. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.
    Sinzinger H; Schmid P; O'Grady J
    Atherosclerosis; 1999 Apr; 143(2):459-60. PubMed ID: 10217378
    [No Abstract]   [Full Text] [Related]  

  • 5. Statin-induced myositis migrans.
    Sinzinger H
    Wien Klin Wochenschr; 2002 Nov; 114(21-22):943-4. PubMed ID: 12528328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin-associated myopathy with normal creatine kinase levels.
    Phillips PS; Haas RH; Bannykh S; Hathaway S; Gray NL; Kimura BJ; Vladutiu GD; England JD;
    Ann Intern Med; 2002 Oct; 137(7):581-5. PubMed ID: 12353945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels.
    Ann Intern Med; 2002 Oct; 137(7):I45. PubMed ID: 12353973
    [No Abstract]   [Full Text] [Related]  

  • 8. Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy.
    Sinzinger H; Chehne F; Lupattelli G
    Drug Saf; 2002; 25(12):877-83. PubMed ID: 12241128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle symptoms associated with statins: a series of twenty patients.
    Soininen K; Niemi M; Kilkki E; Strandberg T; Kivistö KT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):51-4. PubMed ID: 16433891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.
    Skottheim IB; Gedde-Dahl A; Hejazifar S; Hoel K; Asberg A
    Eur J Pharm Sci; 2008 Apr; 33(4-5):317-25. PubMed ID: 18294823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myopathy due to statins, a dose-dependent effect, and of what kind?].
    León Vázquez F; Llanes De Torres R; Morón Merchante I
    Aten Primaria; 2002; 30(3):188. PubMed ID: 12139858
    [No Abstract]   [Full Text] [Related]  

  • 12. The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
    S Afr Med J; 2002 Aug; 92(8):596-7. PubMed ID: 12244613
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
    Cromwell WC; Ziajka PE
    Am J Cardiol; 2000 Nov; 86(10):1123-7. PubMed ID: 11074211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge.
    Fung EC; Crook MA
    Cardiovasc Ther; 2012 Oct; 30(5):e212-8. PubMed ID: 21884002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
    Voora D; Shah SH; Spasojevic I; Ali S; Reed CR; Salisbury BA; Ginsburg GS
    J Am Coll Cardiol; 2009 Oct; 54(17):1609-16. PubMed ID: 19833260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
    Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM
    J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
    Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
    Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Statin-induced dysphagia].
    Edholm B
    Ugeskr Laeger; 2010 Feb; 172(7):544-5. PubMed ID: 20156405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin-associated exacerbation of myasthenia gravis.
    Cartwright MS; Jeffery DR; Nuss GR; Donofrio PD
    Neurology; 2004 Dec; 63(11):2188. PubMed ID: 15596782
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
    Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
    Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.